Renaissance Technologies LLC Has $1.85 Million Stake in Taysha Gene Therapies, Inc. $TSHA

Renaissance Technologies LLC raised its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 141.5% in the first quarter, HoldingsChannel.com reports. The firm owned 413,203 shares of the company’s stock after purchasing an additional 242,103 shares during the quarter. Renaissance Technologies LLC’s holdings in Taysha Gene Therapies were worth $1,847,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in TSHA. AQR Capital Management LLC increased its holdings in shares of Taysha Gene Therapies by 325.6% during the first quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock worth $150,000 after purchasing an additional 82,545 shares during the period. Rhumbline Advisers boosted its stake in shares of Taysha Gene Therapies by 13.5% in the second quarter. Rhumbline Advisers now owns 233,256 shares of the company’s stock valued at $539,000 after buying an additional 27,794 shares during the period. Prudential Financial Inc. boosted its stake in shares of Taysha Gene Therapies by 50.5% in the second quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock valued at $53,000 after buying an additional 7,650 shares during the period. Invesco Ltd. boosted its stake in shares of Taysha Gene Therapies by 27.4% in the second quarter. Invesco Ltd. now owns 203,671 shares of the company’s stock valued at $470,000 after buying an additional 43,772 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Taysha Gene Therapies during the second quarter worth approximately $184,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Wall Street Analyst Weigh In

TSHA has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Wednesday, June 24th. BMO Capital Markets increased their target price on Taysha Gene Therapies from $10.00 to $14.00 and gave the stock an “outperform” rating in a report on Tuesday, June 23rd. Bank of America raised their price target on Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a research note on Tuesday, June 23rd. Finally, Pivotal Research set a $14.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Taysha Gene Therapies currently has a consensus rating of “Buy” and a consensus target price of $12.77.

Taysha Gene Therapies Stock Up 4.9%

Shares of TSHA opened at $6.68 on Wednesday. The firm has a 50 day simple moving average of $6.08 and a two-hundred day simple moving average of $5.47. The company has a debt-to-equity ratio of 0.23, a current ratio of 14.04 and a quick ratio of 14.04. Taysha Gene Therapies, Inc. has a one year low of $2.69 and a one year high of $7.30. The company has a market cap of $1.92 billion, a P/E ratio of -17.58 and a beta of 1.22.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Research analysts forecast that Taysha Gene Therapies, Inc. will post -0.49 EPS for the current fiscal year.

Insider Buying and Selling at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $6.24, for a total value of $1,248,000.00. Following the sale, the insider directly owned 936,410 shares of the company’s stock, valued at $5,843,198.40. This trade represents a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is currently owned by corporate insiders.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.